Oxford Biomedica PLC Total Voting Rights

RNS Number : 3193G

Oxford Biomedica PLC

01 October 2024

 

 

 

OXB

Total Voting Rights

 

Oxford, UK - 01 October 2024: Oxford Biomedica Plc ( "OXB" or the "Company"; LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company's issued share capital as at the close of business on 30 September 2024 consisted of 105,359,856 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

 

Accordingly, the total number of voting rights in OXB at the date of this notice is 105,359,856.

 

The above figure 105,359,856 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, OXB under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

Enquiries:       

 

Oxford Biomedica plc: Natalie Walter, Company Secretary

Tel: [phone]

 

 

About OXB

 

OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

TVREAKNEDEDLEFA